title: Anti-TNF antibody therapy in Crohn's disease: the risk of a switch.
authors: Gastroenterology Department, CIBER-EHD, IDIBAPS, Hospital Clinic, Barcelona, Spain.
authors: Elena
authors: E
authors: Ricart
authors: Ingrid
authors: I
authors: Ordás
authors: Julián
authors: J
authors: Panés
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D057915:Drug Substitution; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D000068879:Adalimumab